erlotinib hydrochloride has been researched along with naphthoquinones in 5 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (naphthoquinones) | Trials (naphthoquinones) | Recent Studies (post-2010) (naphthoquinones) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 7,110 | 149 | 2,923 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatashita, E; Kita, A; Kuwata, K; Nakagawa, K; Okamoto, I; Okamoto, K; Ono, M; Yamaguchi, H; Yamanaka, K | 1 |
| Bauer, R; Efferth, T; Kretschmer, N; Zhao, Q | 1 |
| Ding, K; Hu, X; Li, QY; Li, YL; Lin, NM; Tan, BQ; Wang, F; Zhang, B; Zhang, C | 1 |
| Chen, P; Dai, CH; Li, J; Long, WG; Shu, Y; Wu, JN; Yuan, RX; Zhu, LH; Zhu, YM | 1 |
| Morishita, M; Nakagawa, K; Nishio, K; Okamoto, I; Okamoto, K; Sakai, K; Shimizu, T; Takeda, M | 1 |
1 trial(s) available for erlotinib hydrochloride and naphthoquinones
| Article | Year |
|---|---|
Phase I safety and pharmacokinetic study of YM155, a potent selective survivin inhibitor, in combination with erlotinib in patients with EGFR TKI refractory advanced non-small cell lung cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Humans; Imidazoles; Lung Neoplasms; Male; Middle Aged; Naphthoquinones; Prognosis; Protein Kinase Inhibitors; Survivin | 2020 |
4 other study(ies) available for erlotinib hydrochloride and naphthoquinones
| Article | Year |
|---|---|
Overcoming erlotinib resistance in EGFR mutation-positive non-small cell lung cancer cells by targeting survivin.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Inhibitor of Apoptosis Proteins; Mice; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Quinazolines; RNA Interference; RNA, Small Interfering; Signal Transduction; Survivin | 2012 |
Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.
Topics: Anthraquinones; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Glioblastoma; Humans; Mitogen-Activated Protein Kinases; Naphthoquinones; Phosphorylation; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction | 2015 |
Shikonin sensitizes wild‑type EGFR NSCLC cells to erlotinib and gefitinib therapy.
Topics: A549 Cells; Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lithospermum; Lung Neoplasms; Mice, Nude; Naphthoquinones; Protein Kinase Inhibitors; Reactive Oxygen Species | 2018 |
YM155 sensitizes non-small cell lung cancer cells to EGFR-tyrosine kinase inhibitors through the mechanism of autophagy induction.
Topics: Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Imidazoles; Lung Neoplasms; Naphthoquinones; Protein Kinase Inhibitors; Survivin | 2018 |